21.87
price down icon9.89%   -2.40
after-market After Hours: 21.93 0.06 +0.27%
loading
Apellis Pharmaceuticals Inc stock is traded at $21.87, with a volume of 2.39M. It is down -9.89% in the last 24 hours and down -13.04% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$24.27
Open:
$23.67
24h Volume:
2.39M
Relative Volume:
1.44
Market Cap:
$2.78B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-10.77
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-9.85%
1M Performance:
-13.04%
6M Performance:
-24.17%
1Y Performance:
-62.79%
1-Day Range:
Value
$21.70
$24.00
1-Week Range:
Value
$21.70
$24.88
52-Week Range:
Value
$21.70
$59.91

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Name
Apellis Pharmaceuticals Inc
Name
Phone
617-977-5700
Name
Address
100 FIFTH AVENUE, WALTHAM, KY
Name
Employee
710
Name
Twitter
@ApellisPharma
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
21.87 2.78B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-17-24 Downgrade Goldman Buy → Neutral
Nov-21-24 Initiated Morgan Stanley Equal-Weight
Oct-25-24 Initiated RBC Capital Mkts Sector Perform
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-16-24 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Neutral
Feb-05-24 Upgrade Jefferies Hold → Buy
Dec-14-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-09-23 Initiated Goldman Buy
Nov-02-23 Initiated Mizuho Neutral
Oct-06-23 Upgrade JP Morgan Neutral → Overweight
Sep-15-23 Upgrade Wells Fargo Equal Weight → Overweight
Aug-29-23 Reiterated Citigroup Buy
Aug-03-23 Downgrade JP Morgan Overweight → Neutral
Aug-01-23 Downgrade BofA Securities Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-10-22 Downgrade Jefferies Buy → Hold
Jul-19-22 Initiated H.C. Wainwright Buy
Jun-17-22 Resumed Stifel Buy
Apr-14-22 Downgrade ROTH Capital Neutral → Sell
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Downgrade ROTH Capital Buy → Neutral
Sep-10-21 Reiterated BMO Capital Markets Outperform
Sep-10-21 Reiterated Credit Suisse Neutral
Sep-10-21 Reiterated Needham Buy
Sep-10-21 Reiterated Oppenheimer Outperform
Sep-10-21 Downgrade Wedbush Outperform → Neutral
Aug-19-21 Initiated Jefferies Buy
Aug-19-21 Upgrade Wedbush Neutral → Outperform
May-21-21 Initiated UBS Buy
Apr-16-21 Initiated Goldman Buy
Nov-19-20 Initiated Needham Buy
Sep-01-20 Initiated Stifel Buy
Jul-20-20 Initiated ROTH Capital Buy
Jun-17-20 Initiated BTIG Research Neutral
Apr-01-20 Initiated Raymond James Strong Buy
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-11-20 Upgrade Wedbush Underperform → Neutral
Jan-07-20 Initiated SVB Leerink Mkt Perform
Dec-19-19 Initiated BofA/Merrill Buy
Nov-22-19 Initiated Wedbush Underperform
Nov-05-19 Initiated Credit Suisse Neutral
Aug-01-19 Reiterated Cantor Fitzgerald Overweight
Jul-12-19 Upgrade JP Morgan Neutral → Overweight
Mar-29-19 Initiated Robert W. Baird Outperform
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Jul-30-18 Upgrade B. Riley FBR Neutral → Buy
May-24-18 Initiated Cantor Fitzgerald Overweight
Apr-12-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

pulisher
Mar 29, 2025

(APLS) Investment Analysis - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 26, 2025

Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech

Mar 26, 2025
pulisher
Mar 25, 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com

Mar 25, 2025
pulisher
Mar 24, 2025

12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey

Mar 24, 2025
pulisher
Mar 24, 2025

Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN

Mar 24, 2025
pulisher
Mar 21, 2025

Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy - Business Wire

Mar 19, 2025
pulisher
Mar 19, 2025

Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

(APLS) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 19, 2025
pulisher
Mar 18, 2025

Apellis Pharmaceuticals executive sells shares valued at $4,542 By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Apellis Pharmaceuticals Beats Investor Suit Over Eye Drug Risks - Bloomberg Law News

Mar 18, 2025
pulisher
Mar 18, 2025

Apellis Pharmaceuticals executive sells shares valued at $4,542 - Investing.com India

Mar 18, 2025
pulisher
Mar 14, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews

Mar 11, 2025
pulisher
Mar 08, 2025

Learn to Evaluate (APLS) using the Charts - news.stocktradersdaily.com

Mar 08, 2025
pulisher
Mar 07, 2025

Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025
pulisher
Mar 06, 2025

Insider Sells Thousands of Apellis Pharmaceuticals Shares! - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha

Mar 05, 2025
pulisher
Mar 05, 2025

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Mar 03, 2025

Apellis Pharmaceuticals Inc Stock (APLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):